

Rosario Menendez

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4115694/rosario-menendez-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

135
papers

4,631
citations

39
h-index

64
g-index

184
ext. papers

6,194
ext. citations

6.9
avg, IF

5.23
L-index

#	Paper	IF	Citations
135	Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 677-86	27.4	306
134	A worldwide perspective of atypical pathogens in community-acquired pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 175, 1086-93	10.2	171
133	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	149
132	Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. <i>Critical Care</i> , 2012 , 16, R93	10.8	133
131	Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 757-62	10.2	128
130	Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. <i>Chest</i> , 2013 , 144, 999-1007	5.3	122
129	Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2016 , 48, 632-47	13.6	120
128	Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. <i>Clinical Infectious Diseases</i> , 2009 , 48, 377-85	11.6	116
127	Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. <i>Respiration</i> , 1998 , 65, 108-13	3.7	107
126	Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1783-90	11.6	106
125	New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1287-1297	10.2	103
124	Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. <i>Critical Care</i> , 2020 , 24, 691	10.8	99
123	Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis. <i>Current Opinion in Pulmonary Medicine</i> , 2008 , 14, 219-27	3	98
122	Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999 , 159, 1868-73	10.2	95
121	Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. <i>Chest</i> , 2009 , 135, 1572-1579	5.3	85
120	Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 153-60	4.7	84
119	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. <i>ERJ Open Research</i> , 2016 , 2,	3.5	84

118	Influence of deviation from guidelines on the outcome of community-acquired pneumonia. <i>Chest</i> , 2002 , 122, 612-7	5.3	81
117	Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. <i>European Respiratory Journal</i> , 2012 , 39, 1144-55	13.6	80
116	Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. <i>Critical Care Medicine</i> , 2011 , 39, 2211-7	1.4	78
115	Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. <i>Archives of Internal Medicine</i> , 2009 , 169, 1515-24		78
114	Global initiative for meticillin-resistant <i>Staphylococcus aureus</i> pneumonia (GLIMP): an international, observational cohort study. <i>Lancet Infectious Diseases</i> , 2016 , 16, 1364-1376	25.5	77
113	Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. <i>Chest</i> , 2012 , 141, 1537-1545	5.3	75
112	Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. <i>Chest</i> , 2013 , 144, 1134-1142	5.3	71
111	A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. <i>Clinical Infectious Diseases</i> , 2009 , 49, 409-16	11.6	70
110	Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. <i>Thorax</i> , 2013 , 68, 1007-14	7.3	66
109	Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort. <i>Chest</i> , 2021 , 160, 187-198	5.3	64
108	Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. <i>Journal of Infection</i> , 2020 , 80, e23-e24	18.9	62
107	Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. <i>Journal of Infection</i> , 2012 , 65, 223-30	18.9	59
106	Burden and risk factors for community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	56
105	Treatment failure in community-acquired pneumonia. <i>Chest</i> , 2007 , 132, 1348-55	5.3	56
104	Tobacco smoking increases the risk for death from pneumococcal pneumonia. <i>Chest</i> , 2014 , 146, 1029-1033	3.7	53
103	Challenges in managing <i>Pseudomonas aeruginosa</i> in non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2016 , 117, 179-89	4.6	51
102	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1482-1493	11.6	44
101	Predictors of Severe Sepsis among Patients Hospitalized for Community-Acquired Pneumonia. <i>PLoS ONE</i> , 2016 , 11, e0145929	3.7	44

100	Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality. <i>EBioMedicine</i> , 2017 , 24, 231-236	8.8	43
99	Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. <i>Chest</i> , 2013 , 143, 1009-1017	5.3	42
98	Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 1241-8	10.2	40
97	A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia. <i>Respiratory Care</i> , 2014 , 59, 1078-85	2.1	36
96	Importance of Aspergillus spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study. <i>Respiratory Research</i> , 2014 , 15, 17	7.3	35
95	Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1482-9	4.7	33
94	Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. <i>European Respiratory Journal</i> , 2015 , 45, 1353-63	13.6	33
93	Thrombocytosis is a marker of poor outcome in community-acquired pneumonia. <i>Chest</i> , 2013 , 143, 767-775	7.5	32
92	Pneumonia. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 25	51.1	31
91	Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. <i>Translational Research</i> , 2021 , 236, 147-159	11	29
90	Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortality. <i>Journal of Infection</i> , 2019 , 78, 423-431	18.9	28
89	Biomarkers and community-acquired pneumonia: tailoring management with biological data. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012 , 33, 266-71	3.9	28
88	Impact of guidelines on outcome: the evidence. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009 , 30, 172-8	3.9	25
87	Lung inflammatory pattern and antibiotic treatment in pneumonia. <i>Respiratory Research</i> , 2015 , 16, 15	7.3	24
86	Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome. <i>Respirology</i> , 2013 , 18, 263-71	3.6	24
85	Validation and comparison of SCAP as a predictive score for identifying low-risk patients in community-acquired pneumonia. <i>Journal of Infection</i> , 2010 , 60, 106-13	18.9	24
84	Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. <i>PLoS ONE</i> , 2017 , 12, e0175171	3.7	24
83	Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 370-378	10.2	23

82	Inflammatory response in mixed viral-bacterial community-acquired pneumonia. <i>BMC Pulmonary Medicine</i> , 2014 , 14, 123	3.5	23
81	Systemic inflammatory response and increased risk for ventilator-associated pneumonia: a preliminary study. <i>Critical Care Medicine</i> , 2009 , 37, 1691-5	1.4	23
80	Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers. <i>Chest</i> , 2019 , 156, 1080-1091	5.3	21
79	Community-Acquired Pneumonia. New Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). <i>Archivos De Bronconeumologia</i> , 2010 , 46, 543-558	0.7	21
78	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. <i>Chest</i> , 2020 , 158, 1896-1911	5.3	20
77	Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. <i>Clinical Drug Investigation</i> , 2016 , 36, 41-53	3.2	20
76	Pneumonia presenting with organ dysfunctions: Causative microorganisms, host factors and outcome. <i>Journal of Infection</i> , 2016 , 73, 419-426	18.9	20
75	Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. <i>Respiratory Research</i> , 2017 , 18, 176	7.3	19
74	Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. <i>Journal of Infection</i> , 2015 , 71, 28-36	18.9	18
73	Reduced Diffusion Capacity in COVID-19 Survivors. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1253-1255	4.7	18
72	Predicting In-Hospital Treatment Failure (≥ 7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 82-92	2	17
71	C-Reactive Protein at Discharge, Diabetes Mellitus and ≥ Hospitalization During Previous Year Predict Early Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015 , 12, 306-14	2	17
70	Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. <i>BMC Infectious Diseases</i> , 2017 , 17, 659	4	17
69	The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. <i>Vaccine</i> , 2017 , 35, 5264-5270	4.1	17
68	RIBRON: The spanish Online Bronchiectasis Registry. Characterization of the First 1912 Patients. <i>Archivos De Bronconeumologia</i> , 2021 , 57, 28-35	0.7	17
67	Age-related risk factors for bacterial aetiology in community-acquired pneumonia. <i>Respirology</i> , 2016 , 21, 1472-1479	3.6	16
66	Predicting treatment failure in patients with community acquired pneumonia: a case-control study. <i>Respiratory Research</i> , 2014 , 15, 75	7.3	16
65	miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. <i>Haematologica</i> , 2021 , 106, 1636-1646	6.6	15

64	Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia. <i>Lancet Respiratory Medicine</i> , 2017 , 5, e35-e36	35.1	14
63	Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study. <i>Respirology</i> , 2014 , 19, 929-35	3.6	14
62	An international perspective on hospitalized patients with viral community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2019 , 60, 54-70	3.9	14
61	Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection. <i>Journal of Infection</i> , 2021 , 82, 261-269	18.9	14
60	From starting mechanical ventilation to ventilator-associated pneumonia, choosing the right moment to start antibiotic treatment. <i>Critical Care</i> , 2016 , 20, 169	10.8	13
59	Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in patients with acute respiratory distress syndrome and abdominal diseases: a preliminary observational study. <i>Critical Care</i> , 2011 , 15, R50	10.8	13
58	Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. <i>Chest</i> , 2017 , 151, 1311-1319	5.3	12
57	Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia. <i>Respirology</i> , 2020 , 25, 543-551	3.6	12
56	Neumonía adquirida en la comunidad. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. <i>Archivos De Bronconeumología</i> , 2020 , 56, 1-10	0.7	11
55	C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). <i>Archivos De Bronconeumología</i> , 2021 , 57, 21-27	0.7	11
54	Simultaneous Depression of Immunological Synapse and Endothelial Injury is Associated with Organ Dysfunction in Community-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	10
53	Pneumonic and non-pneumonic exacerbations in bronchiectasis: Clinical and microbiological differences. <i>Journal of Infection</i> , 2018 , 77, 99-106	18.9	10
52	Severity and outcomes of community acquired pneumonia in asthmatic patients. <i>Respiratory Medicine</i> , 2014 , 108, 1713-22	4.6	10
51	The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia. <i>Clinics in Chest Medicine</i> , 2011 , 32, 491-505	5.3	10
50	Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
49	Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020 , 39, 1513-1525	5.3	9
48	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. <i>PLoS ONE</i> , 2017 , 12, e0178022	3.7	9
47	Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac). <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8

46	Inhaled corticosteroids do not influence the early inflammatory response and clinical presentation of hospitalized subjects with COPD exacerbation. <i>Respiratory Care</i> , 2014 , 59, 1550-9	2.1	8
45	Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. <i>Chest</i> , 2021 , 159, 58-72	5.3	8
44	Comparison of real-time and droplet digital PCR to detect and quantify SARS-CoV-2 RNA in plasma. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13501	4.6	8
43	Impact of microbial ecology on accuracy of surveillance cultures to predict multidrug resistant microorganisms causing ventilator-associated pneumonia. <i>Journal of Infection</i> , 2014 , 69, 333-40	18.9	7
42	Compliance with guidelines-recommended processes in pneumonia: impact of health status and initial signs. <i>PLoS ONE</i> , 2012 , 7, e37570	3.7	7
41	Long-term neuropsychiatric outcomes in COVID-19 survivors: A 1-year longitudinal study. <i>Journal of Internal Medicine</i> , 2021 ,	10.8	7
40	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. <i>Respiratory Medicine</i> , 2018 , 140, 115-121	4.6	6
39	Research in community-acquired pneumonia: the next steps. <i>Intensive Care Medicine</i> , 2017 , 43, 1395-1397	4.5	5
38	Early and Late Cardiovascular Events in Patients Hospitalized for Community-Acquired Pneumonia. <i>Archivos De Bronconeumologia</i> , 2020 , 56, 551-558	0.7	5
37	Neumonía intrahospitalaria. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. <i>Archivos De Bronconeumologia</i> , 2020 , 56, 11-19	0.7	5
36	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. <i>Lancet Respiratory Medicine</i> , 2021 ,	35.1	5
35	Mucoid <i>Pseudomonas aeruginosa</i> alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2019 , 154, 40-46	4.6	4
34	Higher frequency of comorbidities in fully vaccinated patients admitted to ICU due to severe COVID-19: a prospective, multicenter, observational study. <i>European Respiratory Journal</i> , 2021 ,	13.6	4
33	Impact of time to intubation on mortality and pulmonary sequelae in critically ill patients with COVID-19: a prospective cohort study.. <i>Critical Care</i> , 2022 , 26, 18	10.8	4
32	Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 257-265	4.7	4
31	Phenotypic Clustering in Non-Cystic Fibrosis Bronchiectasis Patients: The Role of Eosinophils in Disease Severity. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	4
30	The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients. <i>Critical Care</i> , 2021 , 25, 331	10.8	4
29	Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3

28	The heterogeneity of bronchiectasis patient characteristics, management and outcomes across Europe: Data from the EMBARC registry 2018 ,		3
27	Characteristics of patients with pulmonary non-tuberculous Mycobacterial infection in bronchiectasis: Data from the EMBARC registry 2018 ,		3
26	Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators. <i>Medical Sciences (Basel, Switzerland)</i> , 2020 , 8,	3-3	3
25	The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1075-1085	11.6	3
24	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1087-1097	4-7	3
23	COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. <i>Infection</i> , 2021 , 1	5-8	3
22	Soluble P-Selectin in Acute Exacerbations and Stable Bronchiectasis in Adults. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 1587-1591	4-7	2
21	Influence of environmental conditions and pollution on the incidence of infections. <i>ERJ Open Research</i> , 2017 , 3,	3-5	2
20	One-year mortality after ICU admission due to COVID-19 infection.. <i>Intensive Care Medicine</i> , 2022 , 48, 366	14-5	2
19	Chest physiotherapy in European patients with bronchiectasis: Data from the EMBARC registry 2017 ,		2
18	Primary ciliary dyskinesia in adults with bronchiectasis: Data from the Embarc registry 2018 ,		2
17	Non-cystic fibrosis bronchiectasis: The long road to multidrug resistant bacteria. <i>Community Acquired Infection</i> , 2016 , 3, 110	0	2
16	Differences in Nutritional Status and Inflammatory Biomarkers between Female and Male Patients with Bronchiectasis: A Large-Cohort Study. <i>Biomedicine</i> , 2021 , 9,	4-8	2
15	Meeting the old man's friend. <i>Thorax</i> , 2009 , 64, 1016-7	7-3	1
14	Early and late cardiovascular events in patients hospitalized for community-acquired pneumonia. <i>Archivos De Bronconeumologia</i> , 2020 , 56, 551-558	0-7	1
13	Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5-1	1
12	ICU-Acquired Pneumonia Is Associated with Poor Health Post-COVID-19 Syndrome.. <i>Journal of Clinical Medicine</i> , 2021 , 11,	5-1	1
11	Immune treatment in COVID-19.. <i>Revista Espanola De Quimioterapia</i> , 2022 , 35 Suppl 1, 59-63	1-6	0

10	Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDS. <i>Emerging Microbes and Infections</i> , 1-67	18.9	0
9	Reply to Dual antibiotic therapy for outpatient management of community-acquired pneumonia? <i>Archivos De Bronconeumologia</i> , 2020, 56, 766-767	0.7	
8	Reply to "Dual Antibiotic Therapy for Outpatient Management of Community-Acquired Pneumonia?". <i>Archivos De Bronconeumologia</i> , 2020, 56, 766-767	0.7	
7	Solithromycin: the future of macrolide is now. <i>Annals of Research Hospitals</i> , 2017, 1, 1-1	1.6	
6	Biomarkers and Pneumonia: Should We All be Using Them?. <i>Current Respiratory Medicine Reviews</i> , 2011, 7, 262-267	0.3	
5	Atypical Coverage for Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1289-1290	10.2	
4	Reply to De Maria et al.. <i>Clinical Infectious Diseases</i> , 2005, 40, 1375-1376	11.6	
3	Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 41, 271	5.3	
2	Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections 2020, 212-228		
1	Bronchiectasis and Multidrug-resistant Microorganisms: The Ideal Niche?. <i>Archivos De Bronconeumologia</i> , 2018, 54, 543-544	0.7	